A novel monoclonal antibody therapy cuts LDL cholesterol by half in a high-risk patient population

The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol—the so-called "bad" cholesterol—by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found. Results from the study sponsored by Regeneron, are being presented as "late breaking science" at the American Heart Association Scientific Sessions 2020 on Sunday, November 15, and simultaneously published in The New England Journal of Medicine.